The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial
Open accessAbstract
No effective medical therapy is available for all patients with nonalcoholic steatohepatitis (NASH). Ursodeoxycholic acid (UDCA) has been suggested to be of benefit based on open label clinical studies. We randomized 166 patients with liver biopsy-proven NASH to receive between 13 and 15 mg/kg/d of UDCA or placebo for 2 years. End points included changes in liver test results and liver histology at 2 years of therapy. The treatment groups were comparable at entry with regard to age, gender, risk factors for NASH, serum liver biochemistries, and baseline liver histology. A total of 126 patients completed 2 years of therapy. Pre- and posttreatment liver biopsies were available in 107 patients for review at the end of the study. UDCA was well tolerated and body weight was stable during the study duration. Serum liver biochemistries were stable or improved in both the UDCA and placebo-treated groups. Changes in the degree of steatosis, necroinflammation, or fibrosis that occurred with therapy were not significantly different between the UDCA and placebo groups. In conclusion, 2 years of therapy with UDCA at a dose of 13 to 15 mg/kg/d, although safe and well tolerated, is not better than placebo for patients with NASH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Despite several limitations and methodological differences, there is a strong indication of biochemical effi cacy (ALT reduction) and a good safety pro fi le, but no proof of histological ef fi cacy.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [373]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There are three larger, placebo-controlled trials of UDCA in MASH differing in the dose of UDCA used 373 -375 and only two of them report histological endpoints.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [373]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Self-citationNonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Protection from obesity-induced insulin resistance in mice lacking TNF-α function
Uysal, K. T., Wiesbrock, S. M., Marino, M. W., & Hotamisligil, G. S. (1997) · Nature · doi:10.1038/39335 · Cited by 2,234
Yuan, M., Konstantopoulos, N., Lee, J., Hansen, L., Li, Z.-W., Karin, M., & Shoelson, S. E. (2001) · Science · doi:10.1126/science.1061620 · Cited by 1,884
Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis
Angulo, P., Keach, J. C., Batts, K., & Lindor, K. (1999) · Hepatology · doi:10.1002/hep.510300604 · Cited by 1,708
Self-citationBugianesi, E., Leone, N., Vanni, E., Marchesini, G., Brunello, F., CARUCCI, P., Musso, A., Paolis, P. D., Capussotti, L., Salizzoni, M., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.34168 · Cited by 1,436
Prevalence of and Risk Factors for Hepatic Steatosis in Northern Italy
Bellentani, S., Saccoccio, G., Masutti, F., Crocè, L. S., Brandi, G., Sasso, F., Cristanini, G., & Tiribelli, C. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-2-200001180-00004 · Cited by 1,267
Nonalcoholic fatty liver disease
Clark, J. M., Brancati, F. L., & Diehl, A. M. (2002) · Gastroenterology · doi:10.1053/gast.2002.33573 · Cited by 929
Flagged first, then by citations
Research works printed but not linked: 2
- Neuschwander-Tetri, 2002, Histological improvement in NASH following reduction in insulin resistance with 48-week treatment with PPAR agonist rosiglitazone. abstract., HEPATOLOGY, 36, 379A
- Kobak, 2002, Fat-laden hepatocytes are more prone to cellular necrosis than apoptosis when exposed to hydrophobic bile acids., Gastroenterology, 122, A642
Cited by
Sorted by citations
Items 701–727 of 727
E-Manuscript Article Summaries
Current Oncology Editorial Office (2011) · Current Oncology · doi:10.3747/co.v18i2.897
Fibrosis regression and innovative antifibrotic therapies: from bench to bedside
Berres, M., Zaldivar, M. M., Trautwein, C., & Wasmuth, H. E. (2008) · Springer eBooks · doi:10.1007/978-1-4020-8656-4_16
Lemoine, M., & Serfaty, L. (2011) · EMC - Hépatologie · doi:10.1016/s1155-1976(11)54601-7
Drugs and Mechanisms Related to the Treatment of Nonalcoholic Fatty Liver Disease
牟, 钊. (2021) · Advances in Clinical Medicine · doi:10.12677/acm.2021.1111773
Treatment and Exploration of Non-Alcoholic Fatty Liver Disease in Traditional Chinese Medicine
(2022) · Journal of Contemporary Medical Practice · doi:10.53469/jcmp.2022.04(06).21
Кравчун, Н. А., & Дорош, О. (2012) · PROBLEMS OF ENDOCRINE PATHOLOGY · doi:10.21856/j-pep.2012.4.18
Nonalcoholic fatty liver disease
van Son, K. C., Holleboom, A. G., & Tushuizen, M. E. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-822186-0.00024-9
Murshida, C., & Rejani, H. (2023) · International Ayurvedic Medical Journal · doi:10.46607/iamj1811092023
Андреевна, С. Н., Владимировна, Г. И., & Мазурчик, Н. В. (2023) · Endocrinology News Opinions Training · doi:10.33029/2304-9529-2023-12-3-40-45
BAR502/fibrate conjugates: synthesis, biological evaluation and metabolic profile
Finamore, C., Marino, S. D., Cassiano, C., Napolitano, G., Rapacciuolo, P., Marchianò, S., Biagioli, M., Roselli, R., Giorgio, C. D., Festa, C., et al. (2024) · Frontiers in Chemistry · doi:10.3389/fchem.2024.1425867
Ursodeoxycholic acid in hepatobiliary diseases
Kim, H., & Yoo, J. (2024) · Journal of Korean Medical Association · doi:10.5124/jkma.2024.67.9.603
Tan, H., Yao, H., & Nie, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-21630-5.00003-4
Насрединович, М. С., & Мехтиева, О. А. (2025) · Новые Санкт-Петербургские врачебные ведомости. · doi:10.24884/1609-2201-2024-103-3-41-49
Zabotina, E. E., Khabarova, Y. A., & Stukova, N. Y. (2025) · Experimental and Clinical Gastroenterology · doi:10.31146/1682-8658-ecg-229-9-96-109
Abnormalities of Carbohydrate Metabolism and the Liver
Brigham, D., & Sundaram, S. S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-11760-2.00074-4
Fawaz, R. L. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-11760-2.00076-8
Rebelos, E., & Kounatidis, D. C. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00273-9
Strużek, K., Kwiatkowska, A., Mączka, E., Tracz, W., Świercz, P., Teper, K., Khiralla-Gawlik, S., Strzelecka, A. A., & Basak, A. E. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3662
Kouti, T., Christodoulou, P., Christodoulides, S., Protopapa, F., Michaeloudes, C., & Farazi, P. A. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1767917
Chang, Y. W., Cho, Y. K., Kim, Y. S., Kim, S. E., Cheon, G. J., Kim, J. H., Yang, H. J., Kim, W., Ahn, S. B., Yoon, E. L., et al. (2026) · Journal of Korean Medical Science · doi:10.3346/jkms.2026.41.e89 · Cited by 1
Kumar, K. S., Saraswat, V. A., Kumar, A., Kulkarni, A. V., Goel, A., Shalimar, Shukla, A., Duseja, A. K., Dhiman, R. K., & Aggarwal, R. (2026) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2026.103536
Kehar, M., Ramji, A. S., Swain, M., Singer, A. G., IVERS, N., Schaufert, W., Betel, M., Dasgupta, K., Sebastiani, G., & Patel, K. (2026) · Canadian Liver Journal · doi:10.3138/canlivj-2026-9-3-guidelines
Mahmoud, M., Awali, M., Syn, W.-K., & Qureshi, K. (2026) · Exploration of Digestive Diseases · doi:10.37349/edd.2026.1005137
Syed‐Abdul, M. M. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2749643
Steatosi epatica non alcolica: un aspetto emergente della sindrome metabolica
Manini, R., Moscatiello, S., Ridolfi, V., & Marchesini, G. (2007) · L Endocrinologo · doi:10.1007/bf03344579
12 Niet-alcoholische steatohepatitis
Jansen, P. L. M. (2009) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-313-7437-3_12
Farmakoterapia w niealkoholowej stłuszczeniowej chorobie wątroby
Kolakowski, M., Kukla, M., & Jarosz, M. (2011) · Żywienie Człowieka i Metabolizm
Metadata
- Authors
- Lindor, K. D., Kowdley, K. V., Heathcote, J. E., Harrison, E. M., Jorgensen, R., Angulo, P., Lymp, J. F., Burgart, L., & Colin, P.
- Affiliations
- Mayo Clinic (US)
- University of Washington (US)
- Toronto Western Hospital (CA)
- Mayo Clinic in Arizona (US)
- Corresponding author
- Lindor, Keith D.
- Venue
- Hepatology
- Published
- 2004-03
- Volume
- 39
- Issue
- 3
- Pages
- 770-778
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2139112405
- Cited by
- 727
- References
- 26
- Citations by year
- 2026: 6 · 2025: 18 · 2024: 18 · 2023: 18 · 2022: 19 · 2021: 26 · 2020: 21 · 2019: 27 · 2018: 26 · 2017: 24 · 2016: 33 · 2015: 45 · 2014: 30 · 2013: 40 · 2012: 44
- FWCI
- 35.12
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Baylor University
- Baylor University Medical Center
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- ursodeoxycholic acid, nonalcoholic steatohepatitis, NASH treatment, liver histopathology, steatosis, necroinflammation, liver fibrosis, liver enzymes, placebo comparison, drug safety and tolerability
- MeSH terms
- Alanine Transaminase, Aspartate Aminotransferases, Cholagogues and Choleretics, Double-Blind Method, Fatty Liver, Fibrosis, Humans, Liver, Necrosis, Ursodeoxycholic Acid, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
